Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology
The new funding follows a $51 million round in October 2019. More on the vaccines: Icosavax is working on a COVID-19 vaccine, as well as vaccines to prevent less well known diseases: respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The company launched its COVID program in October, supported in part by $10 million from the Bill & Melinda Gates Foundation. Icosavax’s virus-like particle technology was invented at IPD by Neil King, who serves as chair of the startup’s scientific advisory board. Others contributing to the round include existing investors Qiming Venture Partners USA; Adams Street Partners; Sanofi Ventures; and ND Capital.